Clinical Trials Logo
  1. Home
  2. Advanced Malignant Solid Tumor
  3. NCT05098405

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Advanced Malignant Solid Tumor Clinical Trial

Official title:
A Phase 1, First-in-human, Multicenter, Open-label, Dose-escalation Study to Characterize the Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Clinical Trial Summary

This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40. Preclinical studies suggest that MP0317 may provide benefit for the treatment of tumors known to express high levels of FAP and for which approved therapies have been exhausted. This is the first study of MP0317 in humans and its main purpose is to test its safety and tolerability in patients with advanced solid tumors. This study will also examine the blood levels of MP0317 at several increasing dose levels and a recommended dose for further development will be determined. The recommended dose will be tested in a second part of the study to confirm safety and to further assess the preliminary biologic and anti-tumor activity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05098405
Study type Interventional
Source Molecular Partners AG
Contact
Status Terminated
Phase Phase 1
Start date October 11, 2021
Completion date January 19, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04864379 - Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors Phase 1
Recruiting NCT04165590 - Plasmodium Immunotherapy for Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT06150183 - Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05911984 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05396339 - A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03171220 - Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT04241835 - A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function Phase 1
Active, not recruiting NCT03662815 - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT06166472 - A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor Phase 1
Recruiting NCT05477849 - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors Phase 1
Not yet recruiting NCT04275050 - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets Phase 1
Recruiting NCT04758897 - Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors Phase 1